Skip to main content

RxSight, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Six Months Ended June 30,
20252024
Operating Activities:
Net loss$(19,976)$(15,179)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,5611,927
Provision for bad debts32—
Amortization of right-of-use lease assets—33
Amortization of discount on short-term investments(4,541)(3,578)
Stock-based compensation15,68710,801
Provision for excess and obsolete inventory1,250167
Change in operating assets and liabilities:
Accounts receivable1,960(5,441)
Inventories(4,302)(2,189)
Prepaid and other assets1,742673
Accounts payable(1,491)789
Accrued expenses and other liabilities(5,130)(1,339)
Net cash used in operating activities(13,208)(13,336)
Investing Activities:
Purchases of property and equipment(2,112)(3,490)
Maturities of short-term investments110,000119,000
Purchases of short-term investments(72,381)(206,881)
Net cash provided by (used in) investing activities35,507(91,371)
Financing Activities:
Proceeds from issuance of common stock from public offering—108,100
Proceeds from issuance of common stock2,76413,993
Payments for employee taxes related to stock compensation(1,418)(2,133)
Principal payments on finance lease liabilities(16)(38)
Payments of deferred offering costs—(377)
Payments of debt issuance costs—(80)
Net cash provided by financing activities1,330119,465
Effect of foreign exchange rate on cash, cash equivalents and restricted cash20(4)
Net increase in cash, cash equivalents and restricted cash23,64914,754
Cash, cash equivalents and restricted cash - beginning of period17,45610,402
Cash, cash equivalents and restricted cash - end of period$41,105$25,156
Supplemental disclosure of cash flow information:
Operating cash flows from operating leases1,3831,128
Cash paid for income taxes7024
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations:
Operating lease—9,060
Lease obligations recorded for right-of-use assets:
Operating lease—9,060
Acquisition of property and equipment included in accounts payable and accrued expenses and accrued liabilities250229
Deferred offering and financing costs included in accounts payable and accrued liabilities—392
Reclassification of deferred financing costs—768
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.